ALLERGY THERAPEUTICS PLC Logo

ALLERGY THERAPEUTICS PLC

Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.

AGY | IL

Overview

Corporate Details

ISIN(s):
GB00B02LCQ05
LEI:
213800PQ7AHK7KGVOE23
Country:
United Kingdom
Address:
DOMINION WAY, BN14 8SA WORTHING
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allergy Therapeutics PLC is an international, commercial-stage biotechnology company focused on the treatment and diagnosis of allergic disorders. Leveraging its specialist expertise in immunology, the company researches and develops a portfolio of convenient allergy immunotherapy (AIT) products. A key area of focus is its innovative, aluminum-free vaccines that have the potential to modify or cure allergic diseases. The company markets its products primarily across Europe, aiming to transform the lives of patients by providing effective and convenient treatments for various allergies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:00
Report Publication Announcement
Grass MATA MPL Publications in Allergy Journal
English 19.2 KB
2025-07-21 08:00
Business and Financial Review
Trading update for the year ended 30 June 2025
English 19.9 KB
2025-07-11 08:00
Share Issue/Capital Change
PDMR Dealings
English 38.3 KB
2025-03-31 08:00
Interim Report
Interim Results for six months ended 31 Dec 2024
English 211.9 KB
2025-03-27 08:00
Legal Proceedings Report
Advancement to final phase of PROTECT trial
English 16.8 KB
2025-03-03 08:00
Remuneration Information
New Executive Long Term Incentive Awards
English 42.9 KB
2025-02-27 08:00
Regulatory News Service
Presentations at 2025 AAAAI / WAO Joint Congress
English 15.9 KB
2025-02-17 08:00
Environmental & Social Information
Grass MATA MPL Phase III data published in Allergy
English 17.1 KB
2025-02-14 08:00
Remuneration Information
Grant of Options
English 36.4 KB
2025-01-28 08:00
Earnings Release
Half Year Trading update
English 15.6 KB
2025-01-22 08:00
Share Issue/Capital Change
PDMR Dealing and Total Voting Rights
English 28.0 KB
2025-01-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 32.6 KB
2024-12-19 14:41
Share Issue/Capital Change
Exercise of Options and Total Voting Rights
English 10.1 KB
2024-12-17 17:19
Share Issue/Capital Change
Block Listing Interim Review
English 16.8 KB
2024-12-16 16:33
Declaration of Voting Results & Voting Rights Announcements
Result of Annual General Meeting
English 34.9 KB

Automate Your Workflow. Get a real-time feed of all ALLERGY THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ALLERGY THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.